CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks-A prospective randomized phase III study

被引：8

作者：

Sinn, Marianne

Liersch, Torsten

Gellert, Klaus

Messmann, Helmut

Bechstein, Wolf O.

Waldschmidt, Dirk

Jacobasch, Lutz

Wilhelm, Martin

Rau, Bettina M.

Gruetzmann, Robert

Weinmann, Arndt

Maschmeyer, Georg

Pelzer, Uwe

Stieler, Jens

Striefler, Jana Kaethe

Ghadimi, B. Michael

Bahra, Marcus

Oettle, Helmut

Doerken, Bernd

Riess, Hanno

机构：

[1] Charite, Med Oncol, D-13353 Berlin, Germany

[2] Univ Gottingen, Univ Med Ctr, Dept Gen Visceral & Pediat Surg, D-37073 Gottingen, Germany

[3] Sana Klinikum Lichtenberg, Dept Gen & Visceral Surg, Berlin, Germany

[4] Klinikum Augsburg, Dept Gastroenterol, Augsburg, Germany

[5] Univ Hosp Frankfurt, Dept Gen & Visceral Surg, Frankfurt, Germany

[6] Univ Cologne, Dept Gastroenterol & Hepatol, D-50931 Cologne, Germany

[7] Klinikum Nuernberg, Nurnberg, Germany

[8] Univ Med Rostock, Dept Gen Thorac Vasc & Transplantat Surg, Rostock, Germany

[9] Univ Klinikum Carl Gustav Carus, Dept Gen Thorac & Vasc Surg, Dresden, Germany

[10] Klinikum Johannes Gutenberg Univ, Dept Gastroenterol, Mainz, Germany

[11] Potsdam Klinikum, Potsdam, Germany

[12] Charite, Med Oncol, D-13353 Berlin, Germany

[13] Charite, Dept Gen Visceral & Transplantat Surg, Berlin, Germany

[14] Outpatient Dept Hematol Oncol, Friedrichshafen, Germany

[15] Charite, Campus Virchow Klinikum, Internist Onkol, D-13353 Berlin, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期

关键词：

D O I：

10.1200/jco.2015.33.15_suppl.4007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4007

引用

页数：1

共 50 条

[41] Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial.
Hozaeel, Wael
Pauligk, Claudia
Homann, Nils
Luley, Kim
Kraus, Thomas Werner
Trojan, Jorg
Bechstein, Wolf O.
Grimm, Kersten
Heise, Bettina
Schmiegel, Wolff
Pink, Daniel
Al-Batran, Salah-Eddin
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[42] Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial.
Al-Batran, Salah-Eddin
Reichart, Alexander
Bankstahl, Ulli Simone
Pauligk, Claudia
Kraus, Thomas Werner
Bechstein, Wolf Otto
Trojan, Jorg
Behrend, Matthias
Potenberg, Jochem
Homann, Nils
Venerito, Marino
Bohle, Wolfram
Varvenne, Michael
Bolling, Claus
Behringer, Dirk M.
Kratz-Alber, Karsten
Siegler, Gabriele Margareta
Hozaeel, Wael
Goetze, Thorsten Oliver
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[43] A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic canceraEuro
O'Neil, B. H.
Scott, A. J.
Ma, W. W.
Cohen, S. J.
Aisner, D. L.
Menter, A. R.
Tejani, M. A.
Cho, J. K.
Granfortuna, J.
Coveler, L.
Olowokure, O. O.
Baranda, J. C.
Cusnir, M.
Phillip, P.
Boles, J.
Nazemzadeh, R.
Rarick, M.
Cohen, D. J.
Radford, J.
Fehrenbacher, L.
Bajaj, R.
Bathini, V.
Fanta, P.
Berlin, J.
McRee, A. J.
Maguire, R.
Wilhelm, F.
Maniar, M.
Jimeno, A.
Gomes, C. L.
Messersmith, W. A.
ANNALS OF ONCOLOGY, 2015, 26 (09) : 1923 - 1929
[44] APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC).
Tempero, Margaret A.
Cardin, Dana Backlund
Goldstein, David
O'Reilly, Eileen Mary
Philip, Agop Philip
Riess, Hanno
Macarulla, Teresa
Yung, Lotus
Li, Mingyu
Lu, Brian D.
Biankin, Andrew
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[45] Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer
Tabernero, Josep
Chiorean, E. Gabriela
Infante, Jeffrey R.
Hingorani, Sunil R.
Ganju, Vinod
Weekes, Colin
Scheithauer, Werner
Ramanathan, Ramesh K.
Goldstein, David
Penenberg, Darryl N.
Romano, Alfredo
Ferrara, Stefano
Von Hoff, Daniel D.
ONCOLOGIST, 2015, 20 (02): : 143 - 150
[46] A randomized phase II trial of adjuvant chemotherapy with S-1 versus S-1 and gemcitabine (GS) versus gemcitabine alone (GEM) in patients with resected pancreatic cancer (CAP-002 study).
Yoshitomi, Hideyuki
Shimizu, Hiroaki
Yoshidome, Hiroyuki
Ohtsuka, Masayuki
Kato, Atsushi
Furukawa, Katsunori
Takayashiki, Tsukasa
Kuboki, Satoshi
Okamura, Daiki
Suzuki, Daisuke
Nakajima, Masayuki
Aida, Toshiaki
Miyazaki, Masaru
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[47] A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic Cancer (CHIPAC)
Theile, Susann
Johansen, Julia Sidenius
Nielsen, Dorte Lisbet
Jensen, Benny Vittrup
Hansen, Carsten Palnaes
Hasselby, Jane Preuss
Eiriksson, Sverrir Vidalin
Chen, Inna Markovna
PHARMACEUTICS, 2022, 14 (03)
[48] Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
Reham Abdel-Wahab
Gauri R. Varadhachary
Priya R. Bhosale
Xuemei Wang
David R. Fogelman
Rachna T. Shroff
Michael J. Overman
Robert A. Wolff
Milind Javle
Journal of Hematology & Oncology, 11
[49] Gemcitabine plus erlotinib (GE) followed by capecitabine (C) versus capecitabine plus erlotinib (CE) followed by gemcitabine (G) in advanced pancreatic cancer (APC): A randomized, cross-over phase III trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
Boeck, S. H.
Vehling-Kaiser, U.
Waldschmidt, D.
Kettner, E.
Maerten, A.
Winkelmann, C.
Klein, S.
Kojouharoff, G.
Jung, A.
Heinemann, V.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
[50] Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
Abdel-Wahab, Reham
Varadhachary, Gauri R.
Bhosale, Priya R.
Wang, Xuemei
Fogelman, David R.
Shroff, Rachna T.
Overman, Michael J.
Wolff, Robert A.
Javle, Milind
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11

← 1 2 3 4 5 →